Low-dose glucocorticoids in hyperandrogenism;Efecto de bajas dosis de glucocorticoides en el hiperandrogenismo

Medicina

Volumn 67, Issue 3, 2007, Pages 247-252

  Rizzo, Leonardo ^a   Dobrovsky, Viviana ^a   Danilowicz, Karina ^a   Kral, Martha ^a   Cross, Graciela ^a   Serra, Hector A ^a   Bruno, Oscar D ^a  

^a UNIVERSIDAD DE BUENOS AIRES   (Argentina)

Author keywords

Cortisol secretion; Glucocorticoids; Hyperandrogenism

Indexed keywords

ANDROGEN; BETAMETHASONE; GLUCOCORTICOID; HYDROCORTISONE; METHYLPREDNISOLONE; SEX HORMONE BINDING GLOBULIN; TESTOSTERONE;

ABSENCE OF SIDE EFFECTS; ADOLESCENT; ADULT; ANDROGEN BLOOD LEVEL; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; FEMALE FERTILITY; FOLLICULAR PHASE; FOLLOW UP; HORMONE DETERMINATION; HORMONE RELEASE; HUMAN; HYDROCORTISONE BLOOD LEVEL; HYPERANDROGENISM; LOW DRUG DOSE; MENSTRUAL IRREGULARITY; OUTCOME ASSESSMENT; SINGLE DRUG DOSE; TESTOSTERONE BLOOD LEVEL;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; ANALYSIS OF VARIANCE; ANDROGENS; BETAMETHASONE; CLINICAL PROTOCOLS; DRUG ADMINISTRATION SCHEDULE; FEMALE; GLUCOCORTICOIDS; HUMANS; HYDROCORTISONE; HYPERANDROGENISM; METHYLPREDNISOLONE; TESTOSTERONE; TREATMENT OUTCOME;

EID: 34447340208     PISSN: 00257680     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. McKenna TJ, Cunningham SK. The pathogenesis of adrenal and extra adrenal hyperandrogenism. J Steroid Biochem Mol Biol 1993; 45: 117-21.
2. Bruno OD, Arebalo-Cross G, Kral M, et al. Hyperandrogenic syndrome II. Prevalence and biochemical alterations (abstract). Medicina (Buenos Aires) 1989; 49: 453-4.
3. Ferriman D, Gallwey JD. Clinical assessment of body hair growth in women. J Clin Endocrinol Metab 1961; 21: 144-7.
4. Rosner W. Steroid hormones: Synthesis, metabolism and action in health and disease. Endocrinol Metab Clin North Am 1991; 20: 697-720.
5. Redmond GP. Androgenic disorders of women: Diagnostic and therapeutic decision making. Am J Med 1995; 98: 120S-129S.
6. Caufriez A, Arebalo-Cross G, Kral M, et al. A decrease in sex hormone-binding-globulin levels is a sensitive marker of hirsutism in adolescent girls. 74th Annual Meeting of the Endocrine Society San Antonio, Texas. June 24-27, 1992.
7. Steinberger E, Rodríguez-Rigaud LJ, Petak SM, Weidman ER, Smith KD, Ayala C. Glucocorticoid therapy in hyperandrogenism. Baillieres Clin Obstet Gynaecol 1990; 4: 457-71.
8. Nader S, Rodriguez-Rigau LJ, Smith KD, Steinberger E. Acne and hyperandrogenism: impact of lowering androgen levels with glucocorticoid treatment. J Am Acad Dermatol 1984; 11: 256-9.
9. Carmina E, Lobo RA. The addition of dexamethasone to antiandrogen therapy for hirsutism prolongs the duration of remission. Fertil Steril 1998; 69: 1075-9.
10. The Rotterdam ESRE/ASRM-sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 2004; 19: 41-7.
11. Södergard R, Bäckström T, Shanbag V, Carstensen H. Calculation of free and bound fractions of testosterone and estradiol-17beta to human plasma proteins at body temperature. J Steroid Biochem 1982; 16: 801-8.
12. Harter JG. Corticosteroids: their physiologic use in allergic diseases. N Y State J Med 1966; 66: 827-40.
13. Loughlin T, Cunningham S, Moore A, Culliton M, Smyth PP, McKenna TJ. Adrenal abnormalities in polycystic ovary syndrome. J Clin Endocrinol Metab 1986; 62: 142-7.
14. McKenna TJ. Pathogenesis and treatment of polycystic ovary syndrome. N Eng J Med 1988; 318: 558-62.
15. Carmina E, Lobo RA. Adrenal hyperandrogenism in the pathophysiology of polycystic ovary syndrome. J Endocrinol Invest 1998; 21: 580-8.
16. Azziz R, Black VY, Knochenhauer ES, Hines GA, Boots LR. Ovulation after glucocorticoid suppression of adrenal androgens in the polycystic ovary syndrome is not predicted by the basal dehydroepiandrosterone sulfate level. J Clin Endocrinol Metab 1999; 84: 946-50.
17. Baumann EE, Rosenfield RL. Polycystic ovary syndrome in adolescence. The Endocrinologist 2002; 12: 333-48.
18. Rittmaster RS, Loriaux DL, Cutler GB. Sensitivity of cortisol and adrenal androgens to dexamethasone suppression in hirsute women. J Clin Endocrinol Metab 1985; 61: 662-6.
19. Devoto E, Aravena L, Gaete X. Prolonged remission of female hyperandrogenism after discontinuing glucocorticoid therapy. Rev Med Chil 1995: 123: 207-14.
20. Redmond GP, Gidwani GP, Gupta MK, et al. Treatment of androgenic disorders with dexamethasone: Dose-response relationship for suppression of dehydroepiandrosterone sulfate. J Am Acad Dermatol 1990; 22: 91-3.
21. Azziz R. Glucocorticoid suppression in the treatment of androgen excess. In: Azziz R, Nestler JE, Dewailly D (eds). Androgen Excess Disorders in Women. Philadelphia: Lippincott-Raven 1997, pp 737-46.
22. Libanati CR & Baylink DJ. Prevention and treatment of glucocorticoid-induced osteoporosis. Chest 1992; 102: 1426-34.
23. Buckley LM, Leib ES, Cartularo KS, Vacek PM, Cooper SM. Calcium and vitamin D3 supplementation prevents bone loss in the spine secondary to low-dose corticosteroids in patients with rheumatoid arthritis. Ann Intern Med 1996; 125: 961-8.
24. Contreras LN, Rizzo L, Gómez RM, et al. Long-term low-dose glucocorticoid therapy in hyperandrogenized women: Utility and effects on bone mineral content and hypothalamic-pituitary-adrenocortical function. Horm Res 1991; 35: 142-5.
25. Fujieda K, Reyes FI, Blankstein J, Faiman C. Pituitary-adrenal function in women treated with low doses of prednisone. Am J Obstet Gynecol 1980; 137: 962-5.
26. Smith K, Rodriguez-Rigau L, Steinberger E. Response of the adrenal to adrenocorticotropic hormone (ACTH) in hyperandrogenic women treated chronically with low doses of prednisone. Fertil Steril 1982; 38: 202-6.
27. Redmond GP. Treatment of androgenic disorders. In: Redmond GP. Androgenic disorders, New York: Raven Press 1995, ch 13, pp 279-99.
28. Rodriguez-Rigau LJ, Smith KD, Tcholakian RK, Steinberger E. Effect of prednisone on plasma testosterone levels and on duration of phases of the menstrual cycle in hyperandrogenic women. Fertil Steril 1979; 32: 408-13.
29. Lobo RA, Paul W, March CM, Granger L, Kletzky OA. Clomiphene and dexamethasone in women unresponsive to clomiphene alone. Obstet Gynecol 1982; 60: 497-501.
30. Daly DC, Walters CA, Soto-Albors CE, Tohan N, Riddick DH. A randomized study of dexamethasone in ovulation induction with clomiphene citrate. Fertil Steril 1984; 41: 844-8.
31. Crosby PDA, Rittmaster RS. Predictors of clinical response in hirsute women treated with spironolactone. Fertil Steril 1991; 55: 1076-81.
32. Carmina E, Lobo RA. Peripheral androgen blockade versus glandular suppression in the treatment of hirsutism. Obstet Gynecol 1991; 78: 845-9.
33. Rittmaster RS. Medical treatment of androgen-dependent hirsutism. J Clin Endocrinol Metab 1995; 80: 2559-63.
34. Nestler JE. Sex hormone-binding globulin: a marker for hyperinsulinemia/ or insulin resistance. J Clin Endocrinol Metab 1993; 76: 273-4.
35. Jayagopal V, Kilpatrick ES, Jennings PE, Hepburn DA, Atkin SL. The biological variation of testosterone and sex hormone-binding globulin (SHBG) in polycistic ovarian syndrome: Implications for SHBG as a surrogate marker of insulin resistance. J Clin Endocrinol Metab 2003; 88: 1528-33.
36. Ehrmann DA, Barnes RB, Rosenfield RL. Hyperandrogenism, hirsutism, and the polycystic ovary syndrome. In: DeGroot LJ, Jameson JL. (eds) Endocrinology. 5th Ed. Philadelphia: Elsevier Saunders, 2006, ch 157, pp 2963-82.